TY - JOUR
T1 - Cytoglobin
T2 - biochemical, functional and clinical perspective of the newest member of the globin family
AU - Oleksiewicz, Urszula
AU - Liloglou, Triantafillos
AU - Field, John K
AU - Xinarianos, George
PY - 2011/12/1
Y1 - 2011/12/1
N2 - Since the discovery of cytoglobin (Cygb) a decade ago, growing amounts of data have been gathered to characterise Cygb biochemistry, functioning and implication in human pathologies. Its molecular roles remain under investigation, but nitric oxide dioxygenase and lipid peroxidase activities have been demonstrated. Cygb expression increases in response to various stress conditions including hypoxia, oxidative stress and fibrotic stimulation. When exogenously overexpressed, Cygb revealed cytoprotection against these factors. Cygb was shown to be upregulated in fibrosis and neurodegenerative disorders and downregulated in multiple cancer types. CYGB was also found within the minimal region of a hereditary tylosis with oesophageal cancer syndrome, and its expression was reduced in tylotic samples. Recently, Cygb has been shown to inhibit cancer cell growth in vitro, thus confirming its suggested tumour suppressor role. This article aims to review the biochemical and functional aspects of Cygb, its involvement in various pathological conditions and potential clinical utility.
AB - Since the discovery of cytoglobin (Cygb) a decade ago, growing amounts of data have been gathered to characterise Cygb biochemistry, functioning and implication in human pathologies. Its molecular roles remain under investigation, but nitric oxide dioxygenase and lipid peroxidase activities have been demonstrated. Cygb expression increases in response to various stress conditions including hypoxia, oxidative stress and fibrotic stimulation. When exogenously overexpressed, Cygb revealed cytoprotection against these factors. Cygb was shown to be upregulated in fibrosis and neurodegenerative disorders and downregulated in multiple cancer types. CYGB was also found within the minimal region of a hereditary tylosis with oesophageal cancer syndrome, and its expression was reduced in tylotic samples. Recently, Cygb has been shown to inhibit cancer cell growth in vitro, thus confirming its suggested tumour suppressor role. This article aims to review the biochemical and functional aspects of Cygb, its involvement in various pathological conditions and potential clinical utility.
KW - Animals
KW - Cytoglobin
KW - Globins/chemistry
KW - Humans
KW - Molecular Targeted Therapy
U2 - 10.1007/s00018-011-0764-9
DO - 10.1007/s00018-011-0764-9
M3 - Review article
C2 - 21744065
SN - 1420-682X
VL - 68
SP - 3869
EP - 3883
JO - Cellular and Molecular Life Sciences
JF - Cellular and Molecular Life Sciences
IS - 23
ER -